713 related articles for article (PubMed ID: 23329082)
21. Phase I/II study of vemurafenib in patients with unresectable or recurrent melanoma with BRAF(V) (600) mutations.
Yamazaki N; Kiyohara Y; Sugaya N; Uhara H
J Dermatol; 2015 Jul; 42(7):661-6. PubMed ID: 25884515
[TBL] [Abstract][Full Text] [Related]
22. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
Patrawala S; Puzanov I
Future Oncol; 2012 May; 8(5):509-23. PubMed ID: 22646766
[TBL] [Abstract][Full Text] [Related]
23. Safety of vemurafenib in patients with BRAF
Arance AM; Berrocal A; Lopez-Martin JA; de la Cruz-Merino L; Soriano V; Martín Algarra S; Alonso L; Cerezuela P; La Orden B; Espinosa E
Clin Transl Oncol; 2016 Nov; 18(11):1147-1157. PubMed ID: 26983408
[TBL] [Abstract][Full Text] [Related]
24. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib.
Choe CH; McArthur GA; Caro I; Kempen JH; Amaravadi RK
Am J Ophthalmol; 2014 Oct; 158(4):831-837.e2. PubMed ID: 25036880
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
McArthur GA; Chapman PB; Robert C; Larkin J; Haanen JB; Dummer R; Ribas A; Hogg D; Hamid O; Ascierto PA; Garbe C; Testori A; Maio M; Lorigan P; Lebbé C; Jouary T; Schadendorf D; O'Day SJ; Kirkwood JM; Eggermont AM; Dréno B; Sosman JA; Flaherty KT; Yin M; Caro I; Cheng S; Trunzer K; Hauschild A
Lancet Oncol; 2014 Mar; 15(3):323-32. PubMed ID: 24508103
[TBL] [Abstract][Full Text] [Related]
26. Upcoming strategies for the treatment of metastatic melanoma.
Spagnolo F; Queirolo P
Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
[TBL] [Abstract][Full Text] [Related]
27. Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.
Hallmeyer S; Gonzalez R; Lawson DH; Cranmer LD; Linette GP; Puzanov I; Taback B; Cowey CL; Ribas A; Daniels GA; Moore T; Gibney GT; Tawbi H; Whitman E; Lee G; Mun Y; Liu S; Hamid O
Melanoma Res; 2017 Dec; 27(6):585-590. PubMed ID: 29076950
[TBL] [Abstract][Full Text] [Related]
28. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF
Blank CU; Larkin J; Arance AM; Hauschild A; Queirolo P; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Garbe C; Chiarion Sileni V; Mandalà M; Gogas H; Espinosa E; Hospers GAP; Miller WH; Robson S; Makrutzki M; Antic V; Brown MP
Eur J Cancer; 2017 Jul; 79():176-184. PubMed ID: 28501764
[TBL] [Abstract][Full Text] [Related]
29. Vemurafenib and cutaneous adverse events--report of five cases.
Silva Gde B; Mendes AP; de Macedo MP; Pinto CA; Gibbons IL; Duprat Neto JP
An Bras Dermatol; 2015; 90(3 Suppl 1):242-6. PubMed ID: 26312729
[TBL] [Abstract][Full Text] [Related]
30. Dabrafenib therapy for advanced melanoma.
Trinh VA; Davis JE; Anderson JE; Kim KB
Ann Pharmacother; 2014 Apr; 48(4):519-29. PubMed ID: 24259661
[TBL] [Abstract][Full Text] [Related]
31. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
Peters S; Bouchaab H; Zimmerman S; Bucher M; Gaide O; Letovanec I; Homicsko K; Michielin O
Melanoma Res; 2014 Oct; 24(5):496-500. PubMed ID: 25185693
[TBL] [Abstract][Full Text] [Related]
32. Dabrafenib and its potential for the treatment of metastatic melanoma.
Menzies AM; Long GV; Murali R
Drug Des Devel Ther; 2012; 6():391-405. PubMed ID: 23251089
[TBL] [Abstract][Full Text] [Related]
33. BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel.
Gonzalez D; Fearfield L; Nathan P; Tanière P; Wallace A; Brown E; Harwood C; Marsden J; Whittaker S
Br J Dermatol; 2013 Apr; 168(4):700-7. PubMed ID: 23360189
[TBL] [Abstract][Full Text] [Related]
34. Vemurafenib.
Garbe C; Abusaif S; Eigentler TK
Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
[TBL] [Abstract][Full Text] [Related]
35. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma.
Abusaif S; Jradi Z; Held L; Pflugfelder A; Weide B; Meier F; Garbe C; Eigentler TK
Melanoma Res; 2013 Oct; 23(5):396-401. PubMed ID: 23907232
[TBL] [Abstract][Full Text] [Related]
36. Vemurafenib in the French temporary authorization for use metastatic melanoma cohort: a single-centre trial.
Fennira F; Pagès C; Schneider P; Sidina I; Viguier M; Basset-Seguin N; Madjlessi-Ezra N; Madelaine I; Bagot M; Battistella M; Porcher R; Mourah S; Lebbé C
Melanoma Res; 2014 Feb; 24(1):75-82. PubMed ID: 24241686
[TBL] [Abstract][Full Text] [Related]
37. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
[TBL] [Abstract][Full Text] [Related]
38. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
Guerreschi P; Scalbert C; Qassemyar A; Kluza J; Ravasi L; Huglo D; Martinot-Duquennoy V; Formstecher P; Marchetti P; Mortier L
Melanoma Res; 2013 Oct; 23(5):373-80. PubMed ID: 23852164
[TBL] [Abstract][Full Text] [Related]
39. Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.
Heakal Y; Kester M; Savage S
Ann Pharmacother; 2011 Nov; 45(11):1399-405. PubMed ID: 22028422
[TBL] [Abstract][Full Text] [Related]
40. High incidence of naevi-associated BRAF wild-type melanoma and dysplastic naevi under treatment with the class I BRAF inhibitor vemurafenib.
Göppner D; Müller J; Krüger S; Franke I; Gollnick H; Quist SR
Acta Derm Venereol; 2014 Sep; 94(5):517-20. PubMed ID: 24531394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]